Atopic dermatitis (AD) is a chronically relapsing inflammatory skin disease. Influx of activated T cells into the skin lesions represents a hallmark in AD. Recent results indicate a dynamic T-cell-derived cytokine production in AD. In addition to the well-known TH-2 component, chronic lesions and late-phase allergic responses are characterized by an TH-1/TH-0 cytokine pattern. Although there is no doubt that aeroallergens can contribute to the elicitation of acute- and late-phase allergic responses in AD, their role in the immunopathogenesis is controversally discussed. Recent attention has been given to the long-known phenomenon of persistent colonization of AD skin with S. aureus and the potential role of S. aureus-derived superantigens. Evidence from several in vitro and in vivo studies suggests that such bacterial superantigens have the potency to trigger chronic T-cell-mediated skin inflammation. Although these data are certainly suggestive, further clinical studies are required to elucidate the role of bacterial superantigens in initiation, maintenance and, especially, chronicity of skin inflammation.

Keywords:
Atopic dermatitis, Superantigen, Interleukin-4, Interleukin-5, Interferon-=γ, Staphylococcus aureus
1.
Hanifin JM, Rajka G: Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980;92.44–47.
2.
Leung DYM, Rhodes AR, Geha RS, Schneider L, Ring J: Atopic dermatitis; in Fitzpatrick TB, Eisen AZ, Wolff K, Freeberg IM, Austen KF (eds): Dermatology in General Medicine. New York, McGraw-Hill, 1993; pp 1543–1643.
3.
Hoffmann DR, Yamamoto FY, Geller B, Haddad Z: Specific IgE antibodies in atopic eczema. J Allergy Clin Immunol 1975;55:256–267.
4.
Sampson HA, Albergo R: Comparison of results of prick skin tests, RAST, and double-blind placebo-controlled food challenges in children with atopic dermatitis. J Allergy Clin Immunol 1984;74:26–33.
5.
Bock SA, Lee WY, Remigio LK, May CD: Studies of hypersensitivity reactions to foods in infants and children. J Allergy Clin Immunol 1978;62:327–334.
6.
Lacour M, Hauser C: The role of microorganisms in atopic dermatitis. Clin Rev Allergy 1993;11:491–522.
7.
Kieffer M, Bergbrant I-M, Faergemann J, Jemec GB, Ottevanger V, Stahl-Skov P, Svejgaard E: Immune reactions to Pityrosporum ovale in adult patients with atopic and seborrheic dermatitis. J Am Acad Dermatol 1990;22:739–742.
8.
Jones HE, Reinhardt JH, Rinaldi MG: A clinical, mycological and immunological survey for dermatophytosis. Arch Dermatol 1973;107:217–222.
9.
Leung DYM, Rhodes AR, Geha RS: Enumeration of T cell subsets in atopic dermatitis using monoclonal antibodies. J Allergy Clin Immunol 1981;67:450–455.
10.
Leung DYM, Wood N, Dubey D, Rhodes AR, Geha RS: Cellular basis of defective cell-mediated lympholysis in atopic dermatitis. J Immunol 1983;130:1678–1682.
11.
McCoy JP, Hanley-Yanez K, McCaslin D, Tharp MD: Detection of decreased cytotoxic effector CD8+ T lymphocytes in atopic dermatitis by flow cytometry. J Allergy Clin Immunol 1992;89:688–690.
12.
Colver GB, Symons JA, Duff GW: Soluble IL-2 receptor in atopic eczema. Br Med J 1989;298:1426–1428.
13.
Lobitz WC, Honeyman JF, Winkler NW: Suppressed cell mediated immunity in two adults with atopic dermatitis. Br J Dermatol 1972;86:317–328.
14.
Paul WE, Ohara J: B-cell stimulatory factor 1/interleukin 4. Annu Rev Immunol 1987;5:429–459.
15.
Grabstein K, Eisenman J, Mochizuki D, Shanebeck K, Conlon P, Hopp T, March C, Gillis St: Purification to homogeneity of B Cell stimulating factor. J Exp Med 1986;163:1405–1414.
16.
Lehmann DA, Lehmann AA, Coffmann RL: Interleukin-4 causes Isotype switching to IgE in T cell stimulated clonal B cell cultures. J Exp Med 1988;168:853–862.
17.
Gauchat J-E, Lehmann DA, Coffman RL, Bascan H, de Vries JE: Structure and expression of germ-line ε transcripts in human B cells induced by interleukin-4 to switch to IgE production. J Exp Med 1990;172:463–473.
18.
Rousset F, Robert J, Andary M, Bonnin JP, Souillet G, Chrétien I, Briere F, Pene J, de Vries JE: Shifts in interleukin-4 and interferon-γ production by T-cells of patients with elevated serum IgE levels and the modulatory effect of these lymphokines on spontaneous IgE synthesis. J Allergy Clin Immunol 1991;87:58–69.
19.
Vollenweider S, Saurat J-H, Röcken M, Hauser C: Evidence suggesting involvement of interleukin-4 (IL-4) production in spontaneous in vitro IgE synthesis in patients with atopic dermatitis. J Allergy Clin Immunol 1991;87:1088–1095.
20.
Renz H, Jujo K, Bradley KL, Domenico J, Gelfand EW, Leung DYM: Enhanced IL-4 production and IL-4 receptor expression in atopic dermatitis and their modulation by interferon-gamma. J Invest Dermatol 1992;99:403–408.
21.
Snapper CM, Paul WE: Interferon- and B cell stimulatory factor 1 reciprocally regulate Ig isotype production. Science 1987;236:944–947.
22.
Pène J, Rousset F, Chrétien I, Bonnefoy J-Y, Spits H, Yokota T, Arai K.-I, Banchereau J: IgE production by normal human lymphocytes is induced by interleukin-4 and suppressed by interferons and prostaglandin E2. Proc Natl Acad Sci USA 1988;85:6880–6884.
23.
Thyphronitis G, Tsokos GC, June CH, Levine AD, Finkelman FD: IgE secretion by Epstein-Barr virus-infected purified human B lymphocytes is stimulated by interleukin-4 and suppressed by interferon. Proc Natl Acad Sci USA 1989;86:5580–5584.
24.
Romagnani S, Maggi E, Del Prete P, Parronchi P, Macchia D, Tiri A, Ricci M: Role of interleukin-4 and gamma interferon in the regulation of human IgE synthesis: Possible alterations in atopic patients. Int Arch Allergy Appl Immunol 1989;88:111–113.
25.
Mosmann TR, Cherwinski H, Bond MW, Giedlin MH, Coffmann R: Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secretory proteins. J Immunol 1986;136:2348–2357.
26.
Romagnani S: Human TH1 and TH2: Doubt no more. Immunol. Today 1991;12:256–257.
27.
Hu-Li J, Shevach EM, Mizuguchi J, Ohara J, Mosmann T, Paul WE: B cell stimulatory factor-1 (interleukin 4) is a potent costimulant for normal resting T lymphocytes. J Exp Med 1987;165:157–172.
28.
Bradding P, Feather IH, Howarth PH, Müller R, Roberts JA, Britten JPA, Bews TC, HuntOkayama Y, Heusser CH, Bullock GR, Church MK, Holgate ST: Interleukin 4 is localized to and released by human mast cells. J Exp Med 1992;1381–1386.
29.
Möller GM, de Jong TAW, van der Kwast TH, Overbeek SE, Wierenga-Wolf AF, Thepen T, Hoogsteden HC: Immunolocalization of interleukin-4 in eosinophils in the bronchial mucosa of atopic asthmatics. Am J Respir Cell Mol Biol 1996;14:439–443.
30.
Vercelli D, Geha RS: Regulation of IgE synthesis: From membrane to the genes. Springer Semin Immunopathol 1993;15:5–16.
31.
Renz H, Brodie C, Bradley K, Leung DYM, Gelfand EW: Enhancement of IgE production by anti-CD40 antibody in atopic dermatitis. J Allergy Clin Immunol 1994;93:658–668.
32.
Vercelli D, Jahara HH, Arai KI, Geha RS: Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD 23 complex and MHC class II antigens. J Exp Med 1989;169:1295–1307.
33.
Lichtman A, Kurt-Jones EA, Abbas AK: B cell stimulatory factor-1 and not interleukin-2 is the autocrine growth factor for some helper T lymphocytes. Proc Natl Acad Sci USA 1987;84:824–828.
34.
Schleimer RP, Sterbinsky SA, Kaiser J, et al: Interleukin-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium: association with expression of VCAM-1. J Immunol 1992;148:1086–1092.
35.
Bochner BS, Schleimer RP: The role of adhesion molecules in human eosinophil and basophil recruitment. J Allergy Clin Immunol 1994;94:427–438.
36.
Lopez AF, Shannon MF, Chia M-M, Park L, Vadas MA: Regulation of human eosinophil production and function by interleukin-5. Immunol Ser 1992;57:549–571.
37.
Yamaguchi Y, Suda T, Oha S, Toinaga K, Miura Y, Kasahara T: Analysis of the survival of mature human eosinophils: Interleukin-5 prevents apoptosis in mature human eosinophils. Blood 1991;78:2542–2547.
38.
Weller PF: Role of eosinophils in allergy. Curr Opin Immunol 1992;782–787.
39.
Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom BR, Modlin RL: Defining protective responses to pathogens: Cytokine profiles in leprosy lesions. Science 1991;254:277–279.
40.
Salgame P, Abrams JS, Clayberger C, Goldstein H, Convit J, Modlin RL, Bloom BR: Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991;254:279–282.
41.
Pirmez C, Yamamura M, Uyemura M, Paes-Oliveira F, Conceicao S, Modlin RL: Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 1993;91:1390–1395.
42.
Caceres-Dittmar G, Tapia FJ, Sanches MA, Yamamura M, Uyemura K, Modlin RL, Bloom BR, Convit J: Determination of the cytokine profile in american cutaneous leishmaniasis using the polymerase chain reaction. Clin Exp Immunol 1993;91:500–505.
43.
Karp CL, EL Safi SH, Wynn TA, Satti MMH, Kordofani FA, Hashim M, Hag-Ali M, Neva FA, Nutmann TB, Sacks DL: In vivo cytokine profiles in patients with Kala-azar: Marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest 1993;91:1644–1648.
44.
Klyczek KK, Murasko DM, Blank KJ: Interferon-γ, Interferon-α/β, and tumor necrosis factor differentially affect major histokompatibility complex class I expression in murine leukemia virus-induced tumor cell lines. J Immunol 1987;139:2641–2648.
45.
Black CM, Catterall JR, Remington JS: In vivo and in vitro activation of alveolar macrophages by recombinant interferon. J Immunol 1987;138:491–495.
46.
Gajewski TF, Fitch FW: Anti-proliferative effect of IFN-γ in immune regulation. J Immunol 1988;140:4245–4252.
47.
Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, Murphy KM: Development of Th1 CD4+ T cells trough IL-12 produced by Listeria-induced macrophages. Science 1993;260:547–549.
48.
Parronchi P, Mohapatra S, Sampognaro S, Gianarini L, Wahn U, Chong P, Mohapatra S, Maggi E, Renz H, Romagnani S: Effects of interferon-α on cytokine profile. T cell receptor repertoire and peptide reactivity of human allergen-specific T cells. Eur J Immunol 1996;26:697–703.
49.
Gajewski TF, Fitch FW: Anti-proliferative effect of IFN-γ in murine regulation. J Immunol 1988;140:4245–4252.
50.
Vercelli D, Jabara HH, Lauener RP, Geha RS: IL-4 inhibits the synthesis of IFN-γ and induces the synthesis of IgE in human mixed lymphocyte cultures. J Immunol 1990;144:570–573.
51.
Maggi E, Giudizi MG, Biagiotti R, Annunziati F, Manetti R, Piccinni M-P, Parronchi P, Sampognaro S, Giannarini L, Zuccati G, Romagnani S: Th2-like CD8+ T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection. J Exp Med 1994;180:489–495.
52.
Sad S, Marcotte R, Mosmann TR: Cytokine-induced differentiation of precursor mouse CD8+ T cells secreting Th1 or Th2 cytokines. Immunity 1995;2:271–279.
53.
Meissner N, Kussebi F, Ratti H, Baumgarten C, Werfel T, Heusser C, Renz H: A subset of CD8+ T cells from allergic patients produce IL-4 and stimulate IgE production in vitro. Clin Exp Allergy 1997;in press.
54.
Tang MLK, Varigos G, Kemp AS: Reduced interferon-gamma (IFN-γ) secretion with increased IFN-γ mRNA expression in atopic dermatitis: Evidence for a post-transcriptional defect. Clin Exp Immunol 1994;97:483–490.
55.
Jujo K, Renz H, Abe J, Gelfand EW, Leung DYM: Decreased gamma interferon and increased interleukin 4 production promote IgE synthesis in atopic dermatitis. J Allergy Clin Immunol 1992;90:323–330.
56.
Chan SC, Kim JW, Henderson WR, Hanifin JM: Altered prostaglandin E2 regulation of cytokine production in atopic dermatitis. J Immunol 1993;151:3345–3352.
57.
Parronchi P, Macchia D, Picchinni MP, Biswas P, Simonelli C, Maggi E, Ricci M, Ansari AA, Romagnani S: Allergen- and bacterial antigen-specific T cell clones etablished from atopic donors show a different profile of cytokine production. Proc Natl Acad USA 1991;88:4538–4542.
58.
Chan SC, Li SH, Hanifin JM: Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosohodieterase activity and is reversible by phosphodieterase inhibition. J Invest Dermatol 1993;100:681–684.
59.
Willemce R, de Graff-Reitsma CB, Cnossen J, van Vloten WA, Meijer CVLM: Characterization on T cell subpopulations in skin and peripheral blood of patients with cutaneous T cell lymphomas and benign inflammatory dermatoses. J Invest Dermatol 1983;80:60–66.
60.
Zachary CB, Allen MH, Macdonald DM: In situ quantification of T-lymphocyte subsets and Langerhans cells in the inflammatory infiltrate of atopic eczema. Br J Dermatol 1985;112–149.
61.
Leung DYM, Bahn AK, Schneeberger EE, Geha RS: Characterization of the mononuclear cell infiltrate in atopic dermatitis using monoclonal antibodies. J Allergy Clin Immunol 1983;71:47–56.
62.
Bos JD, Hagenara C, Das PK, Krieg SR, Voorn WJ, Kapsenberg ML: Predominance of ‘memory’ T cells (CD4+, CDw29+) over ‘naive’ T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res 1989;81:24–30.
63.
Piletta PA, Wirth S, Hommel L, Saurat JH, Hauser C: Circulating skin-homing T cells in atopic dermatitis: Selective up-regulation of HLA-DR, interleukin-2R and CD30 and decrease after combined UV-A and UV-B phototherapy. Arch. Dermatol. 1996;132(10):1171–1176.
64.
Berg EL, Yoshin T, Rott LS, Robinson MK, Warnock RA, Kishimoto TK, Picker LJ, Butcher EC: The cutaneous lymphocyte antigen is a skin lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1. J Exp Med 1991;174:1461–1466.
65.
Picker LJ, Butcher EC: Physiological and molecular mechanisms of lymphocyte homing. Annu Rev Immunol 1992;10:561–591.
66.
Picker LJ, Martin RJ, Trumble A, Newman LS, Collins PA, Bergstresser PR, Leung DY: Differential expression of lymphocyte homing receptors by human memory/effector T cells in pulmonary versus cutaneous immune effector sites. Eur J Immunol 1994;24:1269–1277.
67.
Albernathy-Carver KJ, Sampson HA, Picker LJ, Leung DYM: Milk induced eczema is associated with the expansion of T cell expressing cutaneous lymphocyte antigen. J Clin Invest 1995;95:913–918.
68.
Mihm MC, Soter NA, Dvorak HF, Austen KJ: The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 1976;67:305–312.
69.
Hamid Q, Boguniewicz M, Leung DYM: Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994;4:870–876.
70.
Thepen T, Langeveld-Wildschut EG, Bihari IC, van Vichen DF, van Reijsen FC, Mudde GC, Bruijnzeel-Koomen CAFM: Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: An immunocytochemical study. J Allergy Clin Immunol 1996;97:828–837.
71.
Tsicopoulos A, Hamid Outayba, Haczku A, Jacobson MR, Durham SR, North J, Barkans J, Corrigan CJ, Meng Q, Moqbel R, Kay B: Kinetics of cell infiltration and cytokine messenger RNA expression after intradermal challenge with allergen and tuberculin in the same atopic individualis. J Allergy Clin Immunol 1994;94:764–772.
72.
Grewe M, Gyufku K, Schopf K, Krutman J: Lesional expression of interferon-gamma in atopic eczema. Lancet 1994;343:25–26.
73.
Van Reijsen FC, Bruijnzell-Koomen CAFM, Kalthoff FS, Maggi E, Romagnani S, Mudde GC: Skin-derived aeroallergen-specific T-cell clones of the TH2 phenotype in patients with atopic dermatitis. J Allergy Clin Immunol 1992;90:184–193.
74.
Van der Heijden FL, Wierenga EA, Bos JD, Kapsenberg ML: High frequency of IL-4 producing CD4+ allergen-specific T lymphocytes in atopic dermatitis lesional skin. J Invest Dermatol 1991;97:389–394.
75.
Werfel T, Morita A, Grewe M, Renz H, Wahn U, Krutmann J, Kapp A: Allergen specificity of skin-infiltrating T cells is not restricted to a type-2 cytokine pattern in chronic skin lesions of atopic dermatitis. J Invest Dermatol 1996;107:871–876.
76.
Hamid O, Naseer T, Minshall EM, Song YL, Boguniewicz M, Leung DYM: In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 1996;98:225–231.
77.
Bock SA, Lee WY, Remigio LK, May CD: Studies of hypersensitivity reactions to foods in infants and children. J Allergy Clin Immunol 1978;62:327–334.
78.
Valenta R, Maurer D, Steiner R, Seiberler S, Sperr WR, Valent P, Spitzhauer S, Kapiotis S, Smolen J, Stingl G: Immunglobulin E response to human proteins in atopic patients. J Invest Dermatol 1996;107:203–208.
79.
Bruijnzeel-Koomen CAFM, Wichen v. DF, Spry CJF, Venge P, Bruijnzeel PLB: Active participation of eosinophils in patch test reactions to inhalent allergens in patients with atopic dermatitis. Br J Dermatol 1988;118:229–238.
80.
Norris PG; Schofield O, Camp RDR: A study of the role of house dust mite in atopic dermatitis. Br J Dermatol 1988;118:435–440.
81.
Mitchel EB, Chapman MD, Pope F, Crow S, Jouhal S, Platts Mills TAE: Basophils in allergen-induced patch test sites in atopic dermatitis Lancet 1982;i:127–130.
82.
Reitamo S, Visa K, Kahonen K, Kyhk K, Stubb S, Salo O: Eczematous reactions in atopic dermatitis patient caused by epicutaneous testing with inhalant allergens. Br J Dermatol 1986;140:303–309.
83.
Adinoff A, Tellez P, Clark R: Atopic dermatitis and aeroallergen contact sensitivity. J Allergy Clin Immunol 1988;81:736–742.
84.
Reitamo S, Visa K, Kähönen K, Käyhko K, Stubb S, Salo OP: Eczematous reactions in atopic patients caused by epicutaneous testing with inhalant allergens. Br J Dermatol 1986;114:303–309.
85.
Dvorak HF: Cutaneous basophil hypersensitivity. J Allergy Clin Immunol 1976;58:229–240.
86.
Mudde GC, van Reijsen FC, Boland GJ, de Gast GC, Bruijnzeel PLB, Bruijnzeel-Koomen CAFN: Allergen presentation by epidermal Langerhans cells from patients with atopic dermatitis in mediated by IgE. Immunology 1990;96:335–341.
87.
Tanaka Y, Anan S, Yoshida H: Immunohistochemical studies in mite antigen induced patch test sites in atopic dermatitis. J Dermatol Sci 1990;1:361–368.
88.
McCluskey RT, Benacerraf B, McCluskey JW: Studies on the specificity of the cellular infiltrate in delayed hypertensivity reactions. J Immunol 1963;90:466–477.
89.
Ramb-Lindauer CH, Feldmann A, Rotte M, Neumann C: Characterization of grass pollen reactive T-cell lines derived from lesional atopic skin. Arch Dermatol Res 1991;283:71–76.
90.
Sager N, Feldmann A, Schilling G, Kreitsch P, Neumann C: House dust mite-specific T-cells in the skin of subjects with atopic dermatitis frequency and lymphokine profile in the allergen patch test. J Allergy Clin Immunol 1992;89:801–810.
91.
Virtanen T, Maggi E, Manetti R, Piccinni M-P, Sampognaro S, Parronchi P, De Carli M, Zuccati G, Romagnani S: No relationship between skin-infiltrating TH2 – like cells and allergen-specific IgE response in atopic dermatitis. J Allergy Clin Immunol 1995;96:411–420.
92.
Frew AJ, O’Hehir RE: What can we learn from studies of lymphocytes present in allergic reaction sites? J Allergy Clin Immunol 1992;89:783–788.
93.
Frew AJ, Kay AB: The relationship between infiltrating CD4+ lymphocytes, activated eosinophils, and the magnitude of the allergen-induced late phase cutaneous reaction in man. J Immunol 1988;141:4158–4164.
94.
Leyden JE, Marpies RR, Kligman AM: Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 1974;90:525–530.
95.
Hauser C, Wuethrich B, Matter L, Wilhelm J, Sonnabend W, Schopfer K: Staphylococcus aureus skin colonization in atopic dermatitis patients. Dermatologica (Basel) 1985;170:35–39.
96.
Aly R, Maibach H, Shinefield H: Microbial flora of atopic dermatitis. Arch Dermatol 1977;113:780–782.
97.
Hanifin JM, Rogge JL: Staphylococcal infections in patients with atopic dermatitis. Arch Dermatol 1977;113:1383–1386.
98.
Cole GW, Silverberg NL: The adherence of Staphylococcus aureus to human corneocytes. Arch Dermatol 1986;122:166–169.
99.
Dahl MC: Staphylococcus aureus and atopic dermatitis. Arch Dermatol 1983;119:840–846.
100.
Roth RR, James WD: Microbiology of the skin: Resident flora ecology, infection. J Am Acad Dermatol 1989;20:367–390.
101.
Bibel DJ, Aly R, Shinefield HR, Maibach HI: The Staphylococcus aureus receptor for fibronectin. J Invest Dermatol 1983;80:494–496.
102.
Kuusela P, Vartio T, Vuento M: Binding sites for streptococci and staphylococci in fibronectin. Infect Immun 1984;45:433–436.
103.
Lopes JD, Reis M, Bretani RR: Presence of laminin receptors in Staphylococcus aureus. Science 1985;229:275–277.
104.
Mythe EB, Kuusela P: Binding of human fibronectin to group A, C, and G streptococci. Infect Immun 1983;40:29–34.
105.
Ryden C, Rubin K, Speciale P: Fibronectin receptors from Staphylococcus aureus. J Biol Chem 1982;258:3396–3401.
106.
Lever R, Hadley K, Downey D, Mackie R: Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988;119:189–198.
107.
Nilsson EJ, Hennings CG, Magnusson J: Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol 1992;27:29–34.
108.
Marrack P, Kappler J: The staphylococcal enterotoxins and their relatives. Science 1990;248:705–711.
109.
Mollick JA, McMasters RL, Grossmann D, Rich R: Localization of a site on bacterial superantigens that determines T cell receptor β chain specificity. J Exp Med 1993;177:283–293.
110.
Kappler JW, Herman A, Clements J, Marrack P: Mutations defining functional regions of the superantigen staphylococcal enterotoxin B. J Exp Med 1992;175:387–396.
111.
Kotzin BL, Leung DYM, Kappler J, Marrack P: Superantigens and human disease. Adv Immunol 1993;54:99–166.
112.
McFadden JP, Noble WC, Camp RDR: Superantigenic exotonin-secreting potential of staphylococci isolated from atopic eczematous skin. Br J Dermatol 1993;128:631–632.
113.
Akiyama H, Toy Y, Kanzaki H, Tada J, Arata J: Prevalence of producers of enterotoxins and toxic skock syndrome toxin-1 among Staphylococcus aureus strains isolated from atopic dermatitis lesions. Arch Dermatol Res 1996;288:418–420.
114.
Leung DY, Harbeck R, Bina P, Reisen RF, Yang E, Norris DA, Hanifin JM, Sampson HA: Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. J Clin Invest 1993;92:1374–1380.
115.
Strange P, Skov L, Lisby S, Nielsen PL, Baadsgaard O: Staphylococcal enterotoxin B applied on intact normal and intact atopic skin induces dermatitis. Arch Dermatol 1996;132:27–33.
116.
Michie CA, Davis T: Atopic dermatitis and staphylococcal superantigens. Lancet 1996;347:329.
117.
Brosius CL, Newburger JC, Burns JC, Leung DYM: Association of Kawasaki syndrome with atopic dermatitis. J Ped Infekt Dis 1988;7:863–866.
118.
Herz U, Schnoy N, Borelli S, Weigl L, Käsbohrer U, Daser A, Wahn U, Köttgen E, Renz H: A hu-SCID mouse model for allergic immune responses: Bacterial superantigen enhances skin inflammation and suppresses IgE production. J Invest Dermatol;in press.
119.
Singer KH, Tuck DT, Sampson HA, Hall RP: Epidermal keratinocytes express the adhesion molecule intercellular adhesion molecule-1 in inflammatory dermatoses. J Invest Dermatol 1989;92:746–750.
120.
Bieber T, Dannenberg B, Ring J, Braun-Falco O: Keratinocytes in lesional skin of atopic eczema bear HLA-DR CD 1a and IgE molecules. Clin Exp Dermatol 1989;14:35–39.
121.
Leung DYM, Cotran RS, Pober JS: Expression of an endothelial leukocyte adhesion molecule (ELAM-1) in elicited late phase allergic skin reactions. J Clin Invest 1987:1805–1810.
122.
Groves RW, Allen MH, Haskard DO, Mac Donald DM: Endothelial leukocyte adhesion molecule-1 in acute and chronic eczema; in Czernielewski JM (ed): Immunological and Pharmacological Aspects of Atopic and Contact Eczema. Pharmacol Skin. Basel, Karger, 1991, pp 85–88.
123.
Leung DYM, Schneeberger EE, Siraganian RP, Geha RS, Bhan AK: The presence of IgE on monocytes/macrophages infiltrating into the skin lesion of atopic dermatitis. Clin Immunol Immunopathol 1987;42:328–337.
124.
Polla BS, Ezekowitz RAB, Leung DYM: Monocytes from patients with severe atopic dermatitis are primed for superoxide production. J Allergy Clin Immunol 1992;89:545.
125.
Bratton DL, Hamid Q, Boguniewicz M, Doherty DE, Kailey JM, Leung DYM: Granulocyte macrophage-colony stimulating factor inhibition of monocyte apoptosis contributes to the chronic monocyte activation in atopic dermatitis. J Clin Invest 1995;95:211–218.
126.
Lester MR, Hofer MF, Renz H, Trumble AE, Gelfand EW, Leung DYM: Modulatory effects of staphylococcal superantigen TSST-1 on IgE synthesis in atopic dermatitis. Clin Immunol Immunopathol 1995;77:332–338.
127.
König B, Neuber K, König W: Responsiveness of peripheral blood mononuclear cell from normal and atopic donors to microbial superantigens. Int Arch Allergy Immunol 1995;106:124–133.
128.
Neuber K, Steinrücke K, Ring J: Staphylococcal enterotoxin B affects in vivo IgE synthesis, Interferon-γ, Interleukin-4 and Interleukin-5 production in atopic eczema. Int Arch Allergy Immunol 1995;107:179–182.
129.
Hofer MF, Lester MR, Schlievert PM; Leung DYM: Upregulation of IgE synthesis by staphylococcal toxic shock syndrome toxin-1 in peripheral blood monuclear cells from patients with atopic dermatitis. Clin Exp Allergy 1995;25:1218–1227.
130.
Leung DYM, Gately M, Trumble A, Ferguson-Darnell B, Schlievert PM, Picker LJ: Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin 12 production. J Exp Med 1995;181:747–753.
131.
Roth R, Faith A, Simon D, Santamaria Babi LF, Verhoef A, Lamb JR, Albert E, Renz H, Blaser K: Allergen-specific skin-homing (CLA+) T cells in atopic dermatitis display restricted epitope-specificity and T cell receptor Vb associated with superantigen reactivity. Possible linkage of DQA1*0501 and DPB1*0401 expression with atopic dermatitis, submitted.
132.
Motala C, Potter PC, Weinberg EG, Malherbe D, Hugher J: Anti-Staphylococcus aureus-specific IgE in atopic dermatitis. J Allergy Clin Immunol 1986;78:583–589.
133.
Toda J, Toi Y, Torigoe R, Akiyama H, Arata J: Presence of IgE antibodies to Staphylococcus aureus and patch test results to Staphylococcus aureus-related antigens in patients with atopic dermatitis (in Japanese). J Dermatol 1994;104:1241–1248.
134.
Kapp A, Schöpf E: Spezifisches IgE gegen Staphylococcus aureus bei Patienten mit atopischer Dermatitis. Hautarzt 1989;40:19–22.
135.
Abramson JS, Dahl MV, Walsh G, Blumenthal MN, Douglas SD, Quie PG: Antistaphylococcal IgE in patients with atopic dermatitis. J Am Acad Dermatol 1982;7:105–110.
136.
Friedmann SJ, Schroeter AL, Homberger HA: IgE antibodies to Staphylococcus aureus: Prevalence in patients with atopic dermatitis. Arch Dermatol 1985;121:869–872.
137.
Schopfer K, Baerlocher K, Price P, Krech U, Quie G, Douglas SD: Staphylococcal IgE antibodies, hyperimmunoglobulinemia E and Staphylococcus aureus infections. N Engl J Med 1979;300:835–838.
138.
Berger M, Kirkpatrick CH, Goldsmity PK, Gallin JI: IgE antibodies to Staphylococcus aureus and Candida albicans in patients with the syndrome of hyperimmunoglobin E and recurrent infections. J Immunol 1980;125:2437–2442.
139.
Geha RS, Reinherz EL, Leung DYM, Scholossman S, Rosen FS: Supressor T cell deficienty in the hyper IgE syndrome. J Clin Invest 1981;68:783–791.
140.
Leung DYM, Cotran RS, Poper JS: Expression of an endothelial leukocyte adhesion molecule (ELAM-1) in elicited late phase allergic skin reaction. J Clin Invest 1991;87:1805–1810.
141.
Jozefczyk Z: Specific human antibodies to entertoxins AB and C of Staphylococcus: their increased synthesis in staphylococcal infection. J Infect Dis 1974;130:1–7.
142.
Tada J, Toi Y, Akiyama H, Arata J: Presence of spezific IgE antibodies to staphylococcal enterotoxins in patients with atopic dermatitis. Eur J Dermatol 1996;6:552–554.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.